No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals
Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.
Publication date: Available online 14 June 2019Source: Personalized Medicine UniverseAuthor(s): Ayaka Nakamura, Minako Abe, Yasuha Ono, Yukie Saeki, Fumika Kono, Hazuki Sakuma, Ayumi Morokuma, Yoshimori Ishihara, Hiroyuki AbeAbstractThe global incidence and mortality rates of colorectal cancer is rising, and has surpassed lung cancer as the highest incidence of all types of cancers in Japan . Standard treatments include surgery and chemotherapy, however immunotherapy using Dendritic Cell (DC) vaccines is also recognized as an effective treatment for many cancers including colorectal cancer. DCs are the most potent antig...
Publication date: Available online 15 June 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Yang Xiong, Ying Wang, Karthik TiruthaniAbstractColorectal cancer (CRC) is predicted to be the 2nd leading cause of cancer-related death in United States in 2019. Immunotherapies such as checkpoint inhibitors have proven efficacy in patients with high level of microsatellite instability and refractory to routine chemotherapy. Despite this, immunotherapy-based treatment is seriously limited by cancer immunogenicity which are evolved to evade immune surveillance in many circumstances. Efforts are made by resear...
ConclusionThe activity and safety of first-line FOLFIRI/aflibercept merit further evaluation in randomized studies.Clinicaltrials.gov registration numberNCT02624726.
Conditions: Colonic Neoplasms; Chemotherapy Effect Interventions: Drug: Anti-PD-1 Monoclonal Antibody JS001; Drug: Chemotherapy Sponsor: Xiangya Hospital of Central South University Not yet recruiting
CONCLUSION: Peritoneal metastasis-derived organoids can be used to evaluate existing HIPEC regimens on an individual-patient level and for development of more effective treatment strategies. Surgical relevance Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) has improved prognosis of patients with peritoneal metastases from colorectal cancer, but disease recurrence is common. More effective and personalized HIPEC is urgently needed. Organoid technology is frequently used for drug screens, as patient-derived organoids can accurately predict clinical therapeutic response in vitro. A panel o...
Conclusion: The high therapeutic efficacy, together with the minimal side effects, of this easily synthesized, pre-targeted system exhibited immense potentiality for the clinical application of DOX delivery.
Conclusions: Anticancer nanotherapies derived from intrinsic anti-inflammatory nanocarriers are promising for targeted combination treatment of inflammation-associated tumors by simultaneously shaping pro-inflammatory microenvironment toward a relatively normal niche sensitive to chemotherapy.
ConclusionsThe meta-analysis of the best, albeit limited, available evidence suggests that temporary loop ileostomy closure during adjuvant chemotherapy following rectal cancer resection may be associated with comparable outcomes to the closure of ileostomy after adjuvant chemotherapy. We encourage future research to concentrate on the completeness of chemotherapy and quality of life which can determine the appropriateness of either approach.
Conclusion: ACT decreased the recurrence rate and distant metastasis rate thus improving prognosis for poorly differentiated or undifferentiated stage IIA colon cancer.
Conclusions: In conclusion, the overexpression of both c-Myb and COX-2 would be of prognostic screening value in patients with CRC.